These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 33609479)

  • 1. New insights into atypical Alzheimer's disease in the era of biomarkers.
    Graff-Radford J; Yong KXX; Apostolova LG; Bouwman FH; Carrillo M; Dickerson BC; Rabinovici GD; Schott JM; Jones DT; Murray ME
    Lancet Neurol; 2021 Mar; 20(3):222-234. PubMed ID: 33609479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes.
    Townley RA; Graff-Radford J; Mantyh WG; Botha H; Polsinelli AJ; Przybelski SA; Machulda MM; Makhlouf AT; Senjem ML; Murray ME; Reichard RR; Savica R; Boeve BF; Drubach DA; Josephs KA; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Jones DT
    Brain Commun; 2020; 2(1):fcaa068. PubMed ID: 32671341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization.
    Bergeron D; Sellami L; Poulin S; Verret L; Bouchard RW; Laforce R
    Dement Geriatr Cogn Disord; 2020; 49(5):518-525. PubMed ID: 33207355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
    Ossenkoppele R; Pijnenburg YA; Perry DC; Cohn-Sheehy BI; Scheltens NM; Vogel JW; Kramer JH; van der Vlies AE; La Joie R; Rosen HJ; van der Flier WM; Grinberg LT; Rozemuller AJ; Huang EJ; van Berckel BN; Miller BL; Barkhof F; Jagust WJ; Scheltens P; Seeley WW; Rabinovici GD
    Brain; 2015 Sep; 138(Pt 9):2732-49. PubMed ID: 26141491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
    Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
    Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Schöll M; Ossenkoppele R; Strandberg O; Palmqvist S; ; Jögi J; Ohlsson T; Smith R; Hansson O
    Brain; 2017 Sep; 140(9):2286-2294. PubMed ID: 29050382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway.
    Kvello-Alme M; Bråthen G; White LR; Sando SB
    J Alzheimers Dis; 2021; 82(3):965-974. PubMed ID: 34120901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease.
    Aziz AL; Giusiano B; Joubert S; Duprat L; Didic M; Gueriot C; Koric L; Boucraut J; Felician O; Ranjeva JP; Guedj E; Ceccaldi M
    Neurobiol Aging; 2017 Jun; 54():22-30. PubMed ID: 28314160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first case series of Chinese patients in Hong Kong with familial Alzheimer's disease compared with those with biomarker-confirmed sporadic late-onset Alzheimer's disease.
    Shea YF; Chu LW; Lee SC; Chan AO
    Hong Kong Med J; 2017 Dec; 23(6):579-85. PubMed ID: 29123074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Typical and atypical appearance of early-onset Alzheimer's disease: A clinical, neuroimaging and neuropathological study.
    Kawakatsu S; Kobayashi R; Hayashi H
    Neuropathology; 2017 Apr; 37(2):150-173. PubMed ID: 28093855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.
    Spina S; La Joie R; Petersen C; Nolan AL; Cuevas D; Cosme C; Hepker M; Hwang JH; Miller ZA; Huang EJ; Karydas AM; Grant H; Boxer AL; Gorno-Tempini ML; Rosen HJ; Kramer JH; Miller BL; Seeley WW; Rabinovici GD; Grinberg LT
    Brain; 2021 Aug; 144(7):2186-2198. PubMed ID: 33693619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Ossenkoppele R; van der Kant R; Hansson O
    Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.